• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of targeted therapy to overcome drug resistance in malignant mesothelioma

Research Project

Project/Area Number 26461183
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Respiratory organ internal medicine
Research InstitutionUniversity of Tsukuba (2015-2017)
Chiba Cancer Center (Research Institute) (2014)

Principal Investigator

SEKINE Ikuo  筑波大学, 医学医療系, 教授 (10508310)

Co-Investigator(Kenkyū-buntansha) 田川 雅敏  千葉県がんセンター(研究所), がん治療開発グループ, 部長 (20171572)
岩澤 俊一郎  千葉大学, 医学(系)研究科(研究院), その他 (00527913)
瀧口 裕一  千葉大学, 医学部附属病院, 教授 (30272321)
Project Period (FY) 2014-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywordsペメトレキセド / 薬物耐性 / CARP / AMPK / ANKRD1 / 悪性中皮腫 / 耐性 / 薬剤耐性 / 増殖因子 / インシュリン様増殖因子 / 化学療法 / 遺伝子発現
Outline of Final Research Achievements

We established pemetrexed (PEM)-resistant mesothelioma cells which did not show any increase of the relevant enzyme activities. We found that expression of CARP was elevated in the PEM-resistant cells with a microarray and Western blot analysis. However, down-regulation of CARP expression with si-RNA did not influence the PEM resistance.Next, we found increased phosphorylated AMPK and p70S6K levels in PEM-resistant cells, and PEM stimulation augmented these phosphorylation. An AMPK activator increased PEM resistance in the parent cells and an inhibitor decreased PEM resistance of the PEM-resistant cells.
These data indicated that constitutive activation of AMPK was associated with PEM resistance.

Report

(5 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report
  • 2014 Research-status Report
  • Research Products

    (14 results)

All 2017 2016 2015

All Journal Article (5 results) (of which Peer Reviewed: 5 results,  Open Access: 5 results,  Acknowledgement Compliant: 1 results) Presentation (9 results) (of which Int'l Joint Research: 5 results)

  • [Journal Article] Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells2017

    • Author(s)
      Qin Yiyang、Sekine Ikuo、Fan Mengmeng、Takiguchi Yuichi、Tada Yuji、Shingyoji Masato、Hanazono Michiko、Yamaguchi Naoto、Tagawa Masatoshi
    • Journal Title

      Cancer Cell International

      Volume: 17 Issue: 1 Pages: 120-120

    • DOI

      10.1186/s12935-017-0493-8

    • NAID

      120007134581

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma2016

    • Author(s)
      Jiang, Y., Zhong, B., Kawamura, K., Morinaga, T., Shingyoji, M., Sekine, I., Tada, Y., Tatsumi, K., Shimada, H., Hiroshima, K. and Tagawa, M.
    • Journal Title

      BMC Cancer

      Volume: 16 Issue: 1 Pages: 455-455

    • DOI

      10.1186/s12885-016-2483-y

    • NAID

      120007129538

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Journal Article] An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.2016

    • Author(s)
      Tada, Y., Hiroshima, K., Shimada, H., Shingyoji, M., Suzuki, T., Umezawa, H., Sekine, I., Takiguchi, Y., Tatsumi, K. and Tagawa, M.: An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol
    • Journal Title

      SpringerPlus

      Volume: 5 Issue: 1 Pages: 195-202

    • DOI

      10.1186/s40064-016-1893-2

    • NAID

      120007129564

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.2015

    • Author(s)
      Tada, Y., Hiroshima, K., Shimada, H., Morishita, N., Shirakawa, T., Matsumoto, K., Shingyoji, M., Sekine, I., Tatsumi, K. and Tagawa, M.
    • Journal Title

      SpringerPlus

      Volume: 4 Issue: 1 Pages: 358-368

    • DOI

      10.1186/s40064-015-1123-3

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Molecular-targeted therapy for malignant mesothelioma2015

    • Author(s)
      Tada, Y., Suzuki, T., Shimada, H., Hiroshima, K., Tatsumi, K. and Tagawa, M
    • Journal Title

      Pleura

      Volume: 1 Pages: 1-11

    • DOI

      10.1177/2373997515600403

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] 悪性中皮腫におけるペメトレキセド耐性はAMPKの活性化が関与する2017

    • Author(s)
      鐘 博雅、関根 郁夫、滝口 裕一、グエン・タオ 、盛永 敬郎、多田 裕司、山口 直人、田川 雅敏
    • Organizer
      第76回日本癌学会総会
    • Related Report
      2017 Annual Research Report
  • [Presentation] E1B-55kDa-defective adenoviruses produced cytotoxicity in combination with MDM2 inhibitors on INK4A/ARF-defective mesothelioma2016

    • Author(s)
      Yuji Tada, Thi Thanh Thao Nguyen, Shuji Kubo, Masato Shingyoji, Ikuo Sekine, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Masatoshi Tagawa
    • Organizer
      2016 ESGCT and ISSCR Congress
    • Place of Presentation
      Florence, Italy
    • Year and Date
      2016-10-18
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] MDMX阻害剤の悪性中皮腫に対する細胞傷害活性はp53非依存的であるが、MDM2阻害剤とは相乗的な併用効果を示すA MDMX inhibitor produces cytotoxicity in a p53-independent manner but achieves synergistic actions with MDM2 inhibitors2016

    • Author(s)
      田川雅敏、盛永敬郎、チョンボウヤア、グエンタオ、久保秀司、関根郁夫、多田裕司、巽浩一郎、島田英昭、廣島健三
    • Organizer
      第75回日本癌学会学術総会
    • Place of Presentation
      パシフィコ横浜(横浜市神奈川県)
    • Year and Date
      2016-10-06
    • Related Report
      2016 Research-status Report
  • [Presentation] 細胞周期促進は増殖性アデノウイルスによるアポトーシスを増強するCell cycle promotion enhances apoptosis induced by replication-competent adenoviruses.2016

    • Author(s)
      盛永敬郎, グエンタオ, チョンボウヤア, 久保秀司, 関根郁夫, 多田裕司,
    • Organizer
      第75回日本癌学会学術総会
    • Place of Presentation
      パシフィコ横浜(横浜市神奈川県)
    • Year and Date
      2016-10-06
    • Related Report
      2016 Research-status Report
  • [Presentation] Enhanced expression of endogenous p53 contributes to E1B55-defective adenoviruses-induced cell death of mesothelioma deleted in the INK4a/ARF region2016

    • Author(s)
      Yuji Tada, Thi Thanh Thao Nguyen, Shuji Kubo, Masato Shingyoji, Ikuo Sekine, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Masatoshi Tagawa
    • Organizer
      Tenth international meeting on replicating oncolytic virus therapeutics
    • Place of Presentation
      Vancouver, Canada
    • Year and Date
      2016-10-01
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] MDM2 and MDM4 inhibitors in combination with adenoviruses up-regulating p53 produce synergistic anti-tumor effects on mesothelioma through augmenting apoptotic processes2016

    • Author(s)
      Masatoshi Tagawa, Taka-aki Kozono, Yiyang Qin, Xue Rao Ning, Takao Morinaga, Shuji Kubo, Masato Shingyoji, Ikuo Sekine, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima
    • Organizer
      22th annual meeting of Japan Society of Gene Therapy
    • Place of Presentation
      Tokyo, Japan
    • Year and Date
      2016-07-28
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] Combination of Forced Transduction of P53 and an Agent That Blocks MDM2-p53 Interactions Produces Synergistic Cytotoxicity on Mesothelioma Defective of the INK4A/ARF Region2016

    • Author(s)
      Masatoshi Tagawa, Takao Morinaga, Zhihan Li, Thao Thi Thanh Nguyen, Boya Zhong, Shuji Kubo, Masato Shingyoji, Ikuo Sekine, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima
    • Organizer
      19th annual meeting of American Society of Gene and Cell Therapy
    • Place of Presentation
      Washington DC, USA
    • Year and Date
      2016-05-04
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] Combination of nutlin-3a and HSP90 inhibitors produces synergistic cytotoxicity on mesothelioma with the wild-type p53.2016

    • Author(s)
      Masatoshi Tagawa, Shinya Okamoto, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Toshio Suzuki, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima
    • Organizer
      The 13th international conference of the international mesothelioma interested group
    • Place of Presentation
      Birmingham, UK
    • Year and Date
      2016-05-01
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] 悪性中皮腫細胞に対してHSP90 阻害剤はAKT とMDMX 活性を阻害し、Nutlin-3a と相乗的な抗腫瘍効果を示す2015

    • Author(s)
      李知瀚、岡本慎也、盛永敬郎、江媛媛、久保秀司、関根郁夫、滝口裕一、多田裕司、巽浩一郎、島田英昭、廣島健三、田川雅敏
    • Organizer
      第74回日本癌学会学術総会
    • Place of Presentation
      名古屋国際会議場(名古屋)
    • Year and Date
      2015-10-08
    • Related Report
      2015 Research-status Report

URL: 

Published: 2014-04-04   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi